Source: MarketScreener

Clarus: Certain Warrants of Clarus Therapeutics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 24-JUL-2022.

(marketscreener.com) Certain Warrants of Clarus Therapeutics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 24-JUL-2022. These Warrants will be under lockup for 90 days starting from 25-APR-2022 to 24-JUL-2022. Details: Executive officers and directors, have agreed, subject to certain exceptions, without the prior written consent of the Maxim Group...https://www.marketscreener.com/quote/stock/CLARUS-THERAPEUTICS-HOLDI-118794445/news/Certain-Warrants-of-Clarus-Therapeutics-Holdings-Inc-are-subject-to-a-Lock-Up-Agreement-Ending-on-41071205/?utm_medium=RSS&utm_content=20220724

Read full article »
Annual Revenue
$5.0-25M
Employees
1-25
Robert E. Dudley's photo - President & CEO of Clarus Therapeutics

President & CEO

Robert E. Dudley

CEO Approval Rating

82/100

Read more